Hepatic Metastasis 12 Years after Nephrectomy for Renal Cell Carcinoma

We report a case in which hepatectomy was performed to treat a patient with metastatic liver cancer 12 years after nephrectomy for renal cell carcinoma. The patient was a 56–year old man. Abdominal CT and MRI showed tumors with diameters of 8.5 cm and 2.5 cm in S2 and S4, respectively, of the liver, and many nodules with a diameter of 1 cm or less, all in the left hepatic lobe. FDG–PET/CT revealed a SUVmax of the tumors of 35, suggesting very high accumulation of FDG. Based on the history of renal cell carcinoma and normal hepatitis virus marker values a diagnosis of metastatic liver cancer from renal cell carcinoma was made. Distant metastasis was found only in the liver. Extended left hepatectomy was carried out, and the histologic findings confirmed metastasis by renal cell carcinoma. The patient had a good surgical postoperative course and was discharged on postoperative day 7. No signs of recurrence were observed at the 20 month follow–up examination. Hepatic metastasis by renal cell carcinoma generally has a poor prognosis, and since no specific, effective pharmacotherapy has been established, hepatectomy is an option, if the safety of surgery can be assured.

[1]  M. Gordon,et al.  Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .

[2]  U. Neumann,et al.  Liver Resection for Metastases from Renal Cell Carcinoma , 2007, World Journal of Surgery.

[3]  D. Nagorney,et al.  Hepatic resection for noncolorectal, nonneuroendocrine metastases , 2005, Journal of Gastrointestinal Surgery.

[4]  H. Bismuth,et al.  Outcome following hepatic resection of metastatic renal tumors: the Paul Brousse Hospital experience. , 2006, HPB.

[5]  T. Wilt,et al.  Immunotherapy for advanced renal cell cancer. , 2015, The Cochrane database of systematic reviews.

[6]  A. Muratore,et al.  Extensive resections for colorectal liver metastases. , 2004, Journal of hepato-biliary-pancreatic surgery.

[7]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[8]  Ying Lu,et al.  Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. , 2002, Radiology.

[9]  J Konishi,et al.  Contribution of PET in the detection of liver metastases from pancreatic tumours. , 1999, Clinical radiology.

[10]  H. Abdel-Nabi,et al.  Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. , 1998, Radiology.

[11]  C. Stief,et al.  Surgery for metachronous solitary liver metastases of renal cell carcinoma. , 1997, The Journal of urology.

[12]  R. Fisher,et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Fisher,et al.  Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Taylor,et al.  Metastatic renal cell cancer and radical nephrectomy: identification of prognostic factors and patient survival. , 1988, The Journal of urology.

[15]  S. Al-Askari,et al.  Aggressive treatment of metastatic renal cancer. , 1986, The Journal of urology.

[16]  J. Dekernion,et al.  Prognostic factors in metastatic renal carcinoma. , 1986, The Journal of urology.

[17]  S. Khoury The treatment of metastasis from renal cell carcinoma. , 1982, Progress in clinical and biological research.

[18]  J. W. Segura,et al.  Renal cell carcinoma: long-term survival and late recurrence. , 1981, The Journal of urology.